This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gross, D. J. Articles by Nagler, A. Search for Related Content PubMed PubMed Citation Articles by Gross, D. J. Articles by Nagler, A.

Treatment with Halofuginone Results in Marked Growth Inhibition of a von Hippel-Lindau Pheochromocytoma in Vivo

Endocrinology and Metabolism Service [D. J. G.] and Department of Bone Marrow Transplantation and Cancer Immunobiology [I. R., L. W., S. S.], Hadassah University Hospital, Jerusalem 91120; Department of Biological Regulation, Weitzmann Institute of Science, Rehovot 76100 [H. D., M. N.]; Institute of Animal Science, The Volcani Center, Bet Dagan [M. P.]; and Department of Bone Marrow Transplantation, Sheba Medical Center, Tel-Hashomer [A. N.], Israel

Halofuginone has recently been shown to inhibit tumor progression of various types of cancers. The antitumoral effect was associated with decreased tumor angiogenesis rather than a direct cytostatic effect on the tumor cells. The antiangiogenic action of the drug could be related to its inhibition of collagen type I synthesis, inhibition of matrix metalloproteinases (MMPs), or via both mechanisms because both collagen synthesis and MMP activity have been shown to be involved in angiogenesis. Vascular endothelial growth factor (VEGF), in addition to its effect on endothelial cell proliferation, has been shown to be a potent inducer of MMP expression. Because von Hippel-Lindau (VHL)-associated tumors express high levels of VEGF, it was of interest to ascertain the potential usefulness of halofuginone for treatment of these tumors. Pheochromocytoma tissue fragments obtained at surgery from a VHL type 2a patient were propagated s.c. in male BALB/c / (nude) mice. For experiments, 2–3-mm tumor fragments were transplanted secondarily s.c. to nude mice. Two treatment groups received halofuginone in standard lab chow at 3 and 5 ppm; control animals received regular chow. All groups were followed for 6 weeks after transplantation. A marked and significant diminution of tumor size and weight was observed in the drug-treated animals (>90% reduction of mean tumor volume for both the 3 and 5 ppm groups). In vivo magnetic resonance imaging analysis of tumors in halofuginone-treated animals showed a significant reduction of vascular functionality. Immunohistochemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells. Taken together, our data indicate that therapy directed at blocking MMP activity (presumably related to excessive VEGF expression in VHL) and reduction of type I collagen deposition curtails angiogenesis and thereby presumably tumor growth in this model system.

This article has been cited by other articles:

				S. Hong, C. Lee, and S.-J. Kim Smad7 Sensitizes Tumor Necrosis Factor Induced Apoptosis through the Inhibition of Antiapoptotic Gene Expression by Suppressing Activation of the Nuclear Factor-{kappa}B Pathway Cancer Res., October 1, 2007; 67(19): 9577 - 9583. [Abstract] [Full Text] [PDF]

				H. AHLMAN Malignant pheochromocytoma: state of the field with future projections. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 449 - 464. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al. Malignant pheochromocytoma: current status and initiatives for future progress Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436. [Abstract] [Full Text] [PDF]